Thermo Fisher occupies an irreplaceable “picks-and-shovels” position across global life sciences, clinical research, and pharmaceutical manufacturing. Its extensive scale, deep customer integration, and mission-critical recurring consumables create high barriers to entry and generate dependable, compounding organic cash flows.
Furthermore, the company’s capital allocation track record remains strong. By pairing steady share repurchases and regular dividend increases with accretive, high-margin acquisitions, the company consistently drives double-digit adjusted earnings growth and deepens competitive moats in clinical trial analytics and advanced biologics.
THERMO FISHER SCIENTIFIC INC. (New York symbol TMO; www.thermofisher.com) lets you tap this leading manufacturer of scientific instruments, laboratory equipment, diagnostic consumables, and life science reagents.
Thermo Fisher recently agreed to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion.
The microbiology business provides mostly clinical researchers antimicrobial susceptibility testing and culture media solutions,; it generated $645 million in revenue last year and has 2,400 employees globally at 13 manufacturing, and research and development sites.
Thermo Fisher plans to use the funds to spur growth in its other businesses.
Meanwhile, the company has just announced the launch of Precure LLC, along with partner Mayo Clinic.
Mayo Clinic is a private American academic medical centre focused on integrated healthcare, education and research. It maintains three major campuses, in Rochester, Minnesota, Jacksonville, Florida and Phoenix/Scottsdale, Arizona.
Precure will aim to create one of the world’s leading biomedical datasets.
Many diseases begin developing biologically years before symptoms lead to a clinical diagnosis. By connecting molecular and clinical data over time, Precure hopes to help researchers better understand these early changes, accelerate drug development and create new opportunities for earlier diagnosis, intervention and more personalized care across a wide range of diseases; those include cancer, cardiometabolic disease, neurological disorders and immune-mediated disease.
[ofie_ad]
Precure will bring together molecular data generated from one million biospecimens, linked with longitudinal clinical information collected over several years, and with the Mayo Clinic’s clinical data and expertise.
Advanced AI and large-scale data analytics will be integral to identifying patterns within these complex datasets and translating them into actionable insights. Mayo Clinic will serve as the majority owner of Precure. Thermo Fisher joins the partnership as a minority owner.
Thermo Fisher’s double-digit earnings growth on strong clinical demand
In the quarter ended June 28, 2026, Thermo Fisher’s revenue rose 10.5%, to $11.99 billion from $10.86 billion a year earlier. Excluding one-time items, per-share earnings rose 12.5%, to $6.03 from $5.36. That beat the consensus forecast of $5.72.
Overall, Thermo Fisher has relied on acquisitions for growth; it also has a high p/e and low yield. That combination leaves the company’s shares vulnerable to a sharp setback on bad corporate news or overall stock market weakness. Still, the company’s success with health technology could produce substantial gains.
Recommendation in Power Growth Investor: Thermo Fisher Scientific is a buy.
